Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 11/20 | 0.36 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.36 |
| ▸ | GABRG2 | P18507 | 5/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 5/20 | 0.33 |
| ▸ | GABRA3 | P34903 | 5/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2285446 | 0.98 | GABRA1 (0.35) | GABRA1GABRA2GABRG2GABRB3GABRA3 | |
| SCHEMBL728744 | 0.71 | GABRA1 (0.38) | GABRA1GABRA2GABRG2GABRB3GABRA3 | |
| SCHEMBL1233444 | 0.66 | ACHE (0.41) | ACHE | |
| SCHEMBL2921118 | 0.63 | ACHE (0.46) | GABRA1GABRG2GABRB3GABRA3ACHE | |
| SCHEMBL29374271 | 0.63 | ACHE (0.46) | GABRA1GABRG2GABRB3GABRA3ACHE | |
| SCHEMBL2186065 | 0.62 | NOS3 (0.40) | GABRA1GABRA2GABRG2GABRB3GABRA3 | |
| SCHEMBL26153071 | 0.60 | NPC1 (0.40) | GABRA1GABRA2GABRG2GABRB3GABRA3 | |
| SCHEMBL8088682 | 0.59 | ACHE (0.46) | GABRA1GABRG2GABRB3GABRA3ACHE | |
| SCHEMBL1712344 | 0.59 | — | — | |
| Ammonia Solution, Strong SCHEMBL28312310 | 0.59 | NPC1 (0.39) | GABRA1GABRA2GABRG2GABRB3GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110195950-A1 | Organic Compounds | NOVARTIS AG | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195950-A1 | Organic Compounds | NR3C2, NR4A1, NR4A2 | GABRA1 1373/4885GABRA2 1152/4885GABRG2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.